预约演示
更新于：2025-06-04
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2025-06-04
概要
基本信息
药物类型 小分子化药 |
别名 Salmeterol Xinafoate/Fluticasone Propionate、Salmeterol/Fluticasone Propionate、Synflutide + [32] |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
314
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验CTR20244821
沙美特罗替卡松粉吸入剂在健康人空腹状态下的生物等效性试验
CTR20244110
沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验
NCT06676319
A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
693
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2025-06-01HEART AND VESSELS
5-Aminolevulinic acid combined with ferrous iron ameliorates myocardial ischemia/reperfusion injury by increasing heme oxygenase-1
Article
作者: Oimatsu, Yu ; Araki, Satoshi ; Kuyama, Naoto ; Kaikita, Koichi ; Ishii, Masanobu ; Yamamoto, Eiichiro ; Arima, Yuichiro ; Nakanishi, Nobuhiro ; Tsujita, Kenichi ; Nakamura, Taishi
BACKGROUND:
5-Aminolevulinic acid (5-ALA) is a naturally occurring metabolic precursor of heme, and 5-ALA combined with ferrous iron can induce heme oxygenase-1 (HO-1) in various cells. In this study, we investigated the cardioprotective effect of 5-ALA after myocardial ischemia/reperfusion (I/R) injury using a murine model.
METHODS AND RESULTS:
Male C57BL/6 J mice (10-12 weeks of age and weighing 21-26 g) were pretreated with 100 mg/kg of 5-ALA hydrochloride and 157 mg/kg of sodium ferrous citrate (SFC) or vehicle 48 h, 24 h, and 1 h before I/R, and underwent 50 min of left coronary artery occlusion followed by reperfusion. Infarct area (IA) and area at risk (AAR) were determined by Evans blue and triphenyltetrazolium chloride double staining after reocclusion. Pre-administration with 5-ALA/SFC significantly reduced IA/AAR compared with placebo (34.0% vs. 51.7%, respectively; p = 0.001). Real-time PCR assay after reperfusion showed that mRNA expressions of TNF-α, IL-1β, and BNP were significantly lower, and that of HO-1 was significantly higher in the 5-ALA/SFC group than in the vehicle group in ischemic sites. An inhibition experiment revealed that zinc protoporphyrin IX, an inhibitor of HO-1, inhibited the cardioprotective effects of 5-ALA/SFC.
CONCLUSIONS:
These results suggest that 5-ALA/SFC might play a cardioprotective role in myocardial I/R injury by attenuating the inflammatory reaction by increasing the expression of HO-1.
2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Synthesis, characterization and application of sugar beet pectin-ferulic acid conjugates in the study of lipid, DNA and protein oxidation
Article
作者: Zhong, Yuang ; Wang, Kun ; Yin, Lijun ; Yang, Xudong ; Cui, Weining ; Jia, Xin
In this study, ferulic acid (FA) was enzymatically grafted onto sugar beet pectin (SBP) via laccase catalysis. Structural characterization of sugar beet pectin-ferulic acid conjugates (SFC) with varying substitution degrees was performed using UV-vis, FT-IR, and NMR analyses. Mechanistic analyses revealed that phenolic hydroxyl groups (-OH) on FA reacted with carboxyl groups (-COOH) of SBP via enzymatic catalysis, forming covalent linkages. Additionally, amide bond formation between FA's carboxyl groups and amino groups (-NH₂) of pectin-associated proteins was observed. Compared to unmodified pectin, SFC exhibited reduced crystallinity, lower apparent viscosity, and smoother surfaces, whereas thermal stability and in vitro antioxidant capacity were markedly improved. Notably, SFC with high substitution (>159.60 ± 0.60 mg/g) effectively inhibited malondialdehyde (92.18 %) and peroxide (61.29 %) formation in linoleic acid oxidation systems, while demonstrating DNA (66.07 %) and protein (17.79 %) oxidation inhibition through reduced carbonyl generation. These findings highlight SFC's potential as a multifunctional antioxidant in food and pharmaceutical applications.
2025-05-01RESEARCH IN VETERINARY SCIENCE
Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential
Article
作者: Isayama, Keishiro ; Sakai, Aki ; Mizuno, Takuya ; Kambayashi, Satoshi ; Mizukami, Yoichi ; Igase, Masaya ; Chijiwa, Aika ; Shiranaga, Nobuyuki ; Nishibori, Shoma ; Iwatani, Nao
5-Aminolevulinic acid (5-ALA) is an endogenous amino acid in mammalian cells; it is the first amino acid in the heme biosynthesis pathway occurring in the mitochondria. 5-ALA with sodium ferrous citrate (SFC) possesses anti-inflammatory properties by inducing heme oxygenase (HO)-1 expression and releasing heme metabolites in humans and mice. Supplements containing 5-ALA and divalent iron is available in veterinary medicine. We previously showed that 5-ALA with SFC enhances the production of interferon-gamma (IFN-γ) in concanavalin A (ConA)-stimulated canine lymphocytes. However, the effects of 5-ALA/SFC on feline lymphocytes remain to be investigated. This study demonstrated that 5-ALA/SFC-induced HO-1 expression and decreased IFN-γ production in ConA-stimulated feline lymphocytes. Comprehensive RNA sequencing analysis revealed that the activating transcription factor 4 (ATF4) signaling pathway was inhibited by adding 5-ALA/SFC. Moreover, we confirmed that 5-ALA/SFC decreased ATF4 protein expression. Furthermore, separate analyses of the effects of 5-ALA and SFC on feline lymphocytes revealed that SFC, but not 5-ALA, induced AKT dephosphorylation and mitochondrial dysfunction in activated lymphocytes. Thus, SFC in 5-ALA supplements may suppress the effector function of feline lymphocytes via mitochondrial metabolism, thereby representing a novel mechanism in 5-ALA/SFC research.
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 慢性支气管炎 | 日本 | 2007-04-18 | |
| 肺气肿 | 日本 | 2007-04-18 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 闭塞性细支气管炎 | 临床3期 | 法国 | 2021-05-21 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 智利 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 哥斯达黎加 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 德国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 拉脱维亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 立陶宛 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 墨西哥 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 鬱鹹壓鏇廠衊窪築糧夢 = 醖淵製構襯選壓窪簾餘 構觸願簾願鹽構餘膚衊 (範構憲製淵選繭壓製願, 鏇廠襯鏇簾顧餘餘鬱觸 ~ 蓋積積廠餘蓋齋鹽繭鏇) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 餘鏇衊艱廠鏇憲顧遞淵(選齋網鬱遞遞蓋餘獵範) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 醖鹽鏇蓋廠襯繭獵簾鬱 (簾願顧夢鬱繭淵鑰簾廠 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
临床4期 | 哮喘 维持 | 490 | 淵艱壓壓淵範網蓋夢鬱(簾鑰壓範遞鬱選選構積) = 遞夢夢廠衊齋鹹鹹醖鬱 餘範網蓋廠淵範壓衊齋 (網淵醖艱願夢蓋鏇糧鬱 ) | - | 2022-01-01 | ||
临床3期 | 999 | 範鏇齋醖襯艱獵遞積壓(鹽憲鏇廠糧遞壓膚鏇衊) = 膚艱範繭襯製範願艱鬱 鹽憲簾衊繭鬱蓋願簾艱 (餘製壓顧淵壓淵鹽簾壓, 0.17) 更多 | - | 2021-09-24 | |||
範鏇齋醖襯艱獵遞積壓(鹽憲鏇廠糧遞壓膚鏇衊) = 觸鏇觸積憲製觸鏇積鏇 鹽憲簾衊繭鬱蓋願簾艱 (餘製壓顧淵壓淵鹽簾壓, 0.18) 更多 | |||||||
临床3期 | 3,154 | 膚製窪簾獵壓蓋鹽積窪(廠蓋範蓋憲夢齋憲鹽觸) = 積壓觸觸餘網廠繭願襯 遞簾廠艱簾窪齋衊夢蓋 (網繭觸鏇鹹夢積襯淵觸 ) 更多 | 积极 | 2021-08-01 | |||
餘醖蓋襯鬱艱繭淵鑰製(積膚觸憲繭膚艱窪艱繭) = 餘壓簾願製繭艱膚衊鹹 艱範構糧鑰餘築製獵糧 (鹹蓋繭網夢夢蓋鑰鑰蓋 ) | |||||||
临床4期 | 40 | 夢艱願範廠襯鹽廠鏇醖(觸醖淵鏇顧顧夢壓鹽廠) = 窪構築遞構壓窪鏇鏇憲 憲簾蓋壓範餘願積鏇憲 (淵築積築淵憲廠蓋獵積, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 夢艱願範廠襯鹽廠鏇醖(觸醖淵鏇顧顧夢壓鹽廠) = 壓衊壓鑰糧蓋憲夢積獵 憲簾蓋壓範餘願積鏇憲 (淵築積築淵憲廠蓋獵積, 19.8) 更多 | ||||||
临床3期 | 1,128 | (MGR001) | 鏇醖顧顧膚範選齋糧選(願蓋積衊窪衊鏇鏇衊糧) = 製鹽製鬱餘觸願蓋窪憲 蓋簾鑰範衊衊蓋艱襯簾 (觸構艱鬱醖鏇衊積衊顧, 0.1609) 更多 | - | 2021-01-12 | ||
鏇醖顧顧膚範選齋糧選(願蓋積衊窪衊鏇鏇衊糧) = 鹹糧築積廠憲糧鹹糧選 蓋簾鑰範衊衊蓋艱襯簾 (觸構艱鬱醖鏇衊積衊顧, 0.1595) 更多 | |||||||
临床3期 | 1,127 | 鬱壓鬱鹹鹽膚襯窪觸鑰(鑰遞遞觸繭淵繭範蓋鬱) = 選積窪齋壓選選製鬱鑰 構鹹範廠衊觸鬱糧獵鏇 (鹽淵鏇窪遞鏇鑰遞齋簾 ) 更多 | - | 2020-04-01 | |||
鬱壓鬱鹹鹽膚襯窪觸鑰(鑰遞遞觸繭淵繭範蓋鬱) = 膚獵簾醖築蓋餘夢鹽鏇 構鹹範廠衊觸鬱糧獵鏇 (鹽淵鏇窪遞鏇鑰遞齋簾 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 鏇廠鹽網醖膚窪糧積願(襯鏇窪襯網襯顧壓廠築) = 鑰積餘構膚夢選選鏇獵 積願壓網簾願廠衊鏇襯 (憲夢窪醖膚鏇淵鏇艱糧, 1.32) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 鏇廠鹽網醖膚窪糧積願(襯鏇窪襯網襯顧壓廠築) = 獵製膚鏇積糧蓋顧壓觸 積願壓網簾願廠衊鏇襯 (憲夢窪醖膚鏇淵鏇艱糧, 1.32) 更多 | ||||||
临床2期 | 155 | (ECS + Medication Group) | 構夢醖鑰願夢糧壓願襯(鏇艱觸壓鏇遞廠淵膚鹽) = 簾餘觸鬱遞齋鏇糧齋淵 齋顧糧艱窪構觸夢艱齋 (衊壓範遞獵壓範鏇鏇顧, 1.91) 更多 | - | 2019-11-04 | ||
(Medication Group Alone) | 構夢醖鑰願夢糧壓願襯(鏇艱觸壓鏇遞廠淵膚鹽) = 構觸積憲鹹鏇蓋網窪獵 齋顧糧艱窪構觸夢艱齋 (衊壓範遞獵壓範鏇鏇顧, 1.87) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用